Trial · NCT02431052
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 | Olumacostat Glasaretil Gel, Vehicle QD | -10.5 | Standard Deviation 9.79 | Lesions | |
| Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 | Olumacostat Glasaretil Gel, Vehicle BID | -11.0 | Standard Deviation 9.04 | Lesions | |
| Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 4.0% QD | -14.6 | Standard Deviation 9.22 | Lesions | |
| Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 7.5% QD | -14.5 | Standard Deviation 9.49 | Lesions | |
| Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 7.5% BID | -15.0 | Standard Deviation 9.35 | Lesions | |
| Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 | Olumacostat Glasaretil Gel, Vehicle QD | -9.3 | Standard Deviation 15.62 | Lesions | |
| Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 | Olumacostat Glasaretil Gel, Vehicle BID | -9.3 | Standard Deviation 15.07 | Lesions | |
| Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 4.0% QD | -15.3 | Standard Deviation 15.17 | Lesions | |
| Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 7.5% QD | -13.4 | Standard Deviation 15.42 | Lesions | |
| Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 7.5% BID | -17.5 | Standard Deviation 15.15 | Lesions | |
| Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 | Olumacostat Glasaretil Gel, Vehicle QD | Success | 4 | Participants | |
| Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 | Olumacostat Glasaretil Gel, Vehicle BID | Success | 6 | Participants | |
| Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 4.0% QD | Success | 23 | Participants | |
| Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 7.5% QD | Success | 21 | Participants | |
| Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 7.5% BID | Success | 26 | Participants | |
| Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 | Olumacostat Glasaretil Gel, Vehicle QD | Failure | 48 | Participants | |
| Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 | Olumacostat Glasaretil Gel, Vehicle BID | Failure | 44 | Participants | |
| Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 4.0% QD | Failure | 83 | Participants | |
| Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 7.5% QD | Failure | 89 | Participants | |
| Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 | Olumacostat Glasaretil Gel, 7.5% BID | Failure | 75 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02431052/results